Breast Cancer
A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+, HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)
- Details
ClinicalTrials.gov ID:
NCT06369285
Diagnosis Type:
NA
USOR Number:
- Address
,
P: